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Abstract: A competitive enzyme immunoassay for the determination of ovine growth hormone (oGH) was developed. The assay is
based on (anti-rabbit IgG) goat IgG-coated microtitreplates, anti-oGH from rabbits, biotinyl-oGH and streptavidin-horseradish
peroxidase. The assay is done directly with 40 µl of plasma and the calibration graph (90% relative binding at 0.38 ± 0.02 ng
ml-1 and 50% relative binding at 3.80 ± 0.18 ng ml-1) is prepared in plasma without measurable endogenous oGH. Recovery in
different plasma samples with added oGH amounted to 96.78 - 100.03 %, and all variabilities were < 10.44. The assay shows no
significant binding of oFSH, oLH, oTSH and oPRL. The assay detects high and low plasma oGH levels within the physiological
variation as well as changes in plasma oGH after stimulation with growth hormone releasing factor. Hence, it offers a reliable
alternative radioimmunoassay. However, a reference method providing evidence of the identity of exogenous oGH will be required
for proving illegal treatment with oGH and for forensic purposes.
Key Words: Enzymatic methods, plasma, ovine growth hormone.

Koyun Kan Plazması Büyüme Hormonu Düzeylerinin Enzim İmmuno Assay Yöntemiyle
Belirlenmesi
Özet: Bu çalışma, koyun plazma büyüme hormonu düzeylerinin belirlenmesinde kullanılabilecek bir enzim immuno assay yönteminin
geliştirilmesi amacıyla yapılmıştır. Yöntem, keçi IgG anti-tavşan IgG’si ile kaplanmış mikrotitre plaklarında, tavşan IgG anti oGH,
biotinle işaretlenmiş oGH ve streptavidin-horseradish peroksidaz kullanılarak yapılmıştır. Assay 40 µl plazma örneklerinin doğrudan
mikrotitre plaklarının yuvalarına verilmesiyle yürütülmüş ve standart çözeltiler ölçülmeyecek düzeyde oGH içeren plazma
örneklerinde hazırlanmıştır. Assayde 90% ve 50% relatif bağlanma 0.38 ± 0.02 ng ml-1 ve 3.80 ± 0.18 ng ml-1 bulunurken, farklı
plazma örneklerine ilave edilen oGH’nın farklı konsantrasyonlarının yeniden bulunmaları 96.78-100.03%, bu değerler arasındaki
varyasyonların 10.44’ten düşük olduğu gözlenmiştir. Assayin oFSH, oLH, oTSH ve oPRL ile çapraz reaksiyonlarının önemli olmadığı,
yöntemin growth releasing faktörle stimülasyondan sonra oluşan değişimler de dahil olmak üzere plazma oGH düzeylerinin
bilinmesinin gerekli olduğu hallerde güvenle kullanılabilecek alternatif bir yöntem olduğu kanısına varılmıştır. Ancak illegal eksojen
oGH kullanımlarının belirlenebilmesi için eksojen oGH’ya özgün bir yönteme de gereksinim duyulmaktadır.
Anahtar Sözcükler: Enzimatik metotlar, plazma, koyun büyüme hormonu.

Introduction
Growing is a complex event controlled by a hormonal
system called the somatotrophin line functioning with a
number of hormones. Growth hormone (GH), insulin,
ketocholamines, thyroid gland hormones, glycocorticoids
and steroids are endocrine controllers which are first in
the somatotrophin line (1). The somatotrophin line starts
from the hyphothalamus to reach peripheral target
organs via hypophyses and the liver. This somatotrophic
line is mainly controlled by GH (2). GH is a protein
hormone built by 191 amino acids (3). The sequence of
GH has species specific differences but closely related
species show the same physiological activity.

It has been found that an impaired somatotrophic line
has a negative effect on growth performance (4, 5). As a
result, GH, Growth Hormone Releasing Factor (GRF),
and IGF-I have been used for stimulating growth
performance (4-6). It has also been thought that there
could be a correlation between growth performance and
plasma GH level, which could be used to evaluate
breeding and production capacity. In addition, it has been
found that the basal GH level is higher in species with a
high breeding capacity than in species with a lower
breeding capacity (7,8).
The important effect of GH on living organisms is that
plasma levels can be used to identify the growth
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performance of organisms. Furthermore, observations on
the basal plasma GH level will provide identification of
exogenous GH supplies in organisms. Generally, Radio
Immuno Assay (RIA) methods have been used for this
purpose, and recently Enzyme Immuno Assay (EIA)
methods have been used for detection (9,10). In this
study, a simple and optimal EIA method was developed
for the identification of sheep plasma GH level.
Materials and Methods
Preparation of biotinyl - oGH Label
500 µg of biotinyl-ε-amino caproic acid Nhydroxysuccinimid ester (Biotin-X-NHS; Sigma,
Diesenhofen, Germany) dissolved in 250 µl N-N-dimethyl
formamide (Aldrich, 22., 705.6) (Reagent A) was used
for coupling with 25 µg of ovine growth hormone
(NIDDK-oGH-1-4, kindly provided by the National
Hormone and Pituitary Program, Baltimore, Maryland,
USA) dissolved in 500 µl 0.01 M NaHCO3 (Reagent B).
100 µl Reagent A and 500 µl Reagent B were mixed and
incubated at room temparature with gentle stirring for 4
h. The reaction was stopped by adding 0.5 mg glycine
(Serva, Heidelberg, Germany) in 200 µl of 50 mM
carbonate buffer (pH 9.98). After overnight incubation at
4 °C, 2 mg of bovine serum albumin (BSA) (Lot Number
05081, Serva - 11930) in 1 ml carbonate buffer was
added to the mixture and dialysed three times against
carbonate buffer at 0 °C overnight. After dialysis, the
conjugate was diluted with assay buffer to achieve a final
concentration of 2.5 µg ml-1, pipetted into aliquots and
stored at -20 oC until used.
oGH Antibody
NIDDK-oGH-2 rabbit antiserum, which has the same
affinity as NIDDK oGH-1-4, was obtained from the
National Hormone and Pituitary Program (NIDKK,
Baltimore, Maryland, USA). This antiserum undergoes no
cross reactions with other hormones (oFSH, oLH, oTSH
and oPRL).
Goat IgG- anti rabbit IgG
A Goat IgG- anti rabbit IgG was kindly supplied by Dr
Klobosa (Institut für Tierzucht und Tierverhalten,
Mariense, Germany).
Enzyme Immunoassay Procedure
First coating: The first coating was achieved by
adding 1 µg of goat antirabbit IgG dissolved in 100 µl of
coating buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6)
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per well of the microtitre plate (Nunc, Rosleilde,
Denmark, No. 439454). The plates were subsequently
incubated for either 2 h at room temperature or
overnight at 0 °C with slight shaking. After incubation,
the plates were decanted.
Second Coating: To achieve saturation of the
remaining binding sites, 350 µl of assay buffer (40 mM
Na2HPO4, 150 mM NaCl, pH 7.2, containing 0.1% BSA)
was added per well and incubated for 15-45 min at room
temperature before subsequent decantation. Non-specific
binding (NSB) ranged from 0.081 to 0.125. Coated
plates can be stored at -20 °C for up to 6 months.
Washing: Prior to use in the assay, the coated plates
were washed twice with 375 µl of 0.05 % Tween 80 per
well.
Assay Protocol: Lyophilized pituitary ovine GH
(NIDDK-oGH-15, National Hormone and Pituitary
Program, Baltimore, Maryland, USA) was dissolved in
0.03 M NaHCO3 in 0.15 M NaCl, pH 10.8, at a
concentration of 100 ng ml-1. Standard solution (0.200 50 ng ml-1 pituitary oGH) was prepared by serial dilution
(steps of 1 : 2) in plasma with undetectable levels of
endogenous ovine GH (≤ 0.2 ng ml-1). Volumes of
standards and unknown plasma samples were diluted in
duplicate in 100 µl per well antibody containing (1 :
500.000) assay buffer using a diluter dispenser
(Hamilton Microlab 1000). The plates were then
incubated with constant gentle shaking for 48 h at 4 °C
and subsequently decanted. After decantation, 0.15 ng
per well of biotinylated oGH in 100 µl assay buffer was
added and incubated for 2 h at 4 °C. Following another
decantation, 20 ng per well of streptavidin peroxidase
(Böhringer, Mannheim, Germany) in 100 µl of assay
buffer was added and incubated for 15 min at 4 °C until
decantation.
Substrate Reaction: The plates were washed four
times with 375 µl of 0.05 % Tween-80, after which 150
µl of substrates A and B (1 : 1) were added per well
[Substrate A, 1.0 g l-1, hydrogen peroxide urea, 18 g l-1
Na2HPO4.2H2O, 10.3 g l-1 citric acid monohydrate, 0.1 ml
l-1 kathon (Rohm and Haas, Frankfurt, Germany), pH
5.0; Substrate B, 500 mg l-1 Tetramethylbenzidine, 40 ml
l-1 dimethylsülfoxide, 10.3 g l-1 citric acid monohydrate,
pH 2.4]. The reaction was stopped with 50 µl of 2 M
H2SO4 per well and the extinction was measured at 450
nm using an eight-channel microtitration plate
photometer (Biotek EL 311).
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Assay Sensitivity

Results
Titration of ovine biotinyl-oGH and anti oGH serum
In order to determine the optimum concentration of
antibody NIDDK-oGH-2 and biotinyl-oGH-1-4, for the
assay a two-dimensional titre determination was
performed. An antibody dilution of 1:10.000-1:640.000
and biotinyl-oGH-1-4 concentrations of 0.15-10 ng per
well were tested. The minimum concentrations of
antibody and biotinyl-oGH-1-4 concentrations of antibody
and biotinyl-oGH-1-4 accepted as suitable for the assay
were taken as those sufficient to achieve on optical
density (OD450) of ca.1. For the actual assay, with an
incubation period of 2 days, an antibody dilution of
1:500.000 and a biotinyl-oGH-1-4 concentration of 0.15
ng per well were chosen.
Assay validation
The influence of incubation temperature on assay
kinetics: to determine the optimum incubation time and
temperature, microtitre plates were incubated for either
4 or 24 h at 22 °C or for either 24 or 48 h at 4 °C
(Figure 1). The relative binding was less in the case of
incubation for 4 h and 24 h at 4 °C than with 24 h at 22
°C and 48 h at 4 °C.
Despite the good relative binding with incubation for
24 h at 22 °C, the slope of the calibration graph was
inferior with low repeatability and higher standard
deviations in the duplicate determinations. For this
reason, an incubation period of 48 h at 4 °C was chosen
as being optimum for the assay.

To determine the possible interference of plasma with
the assay sensitivity, various amounts of plasma (10, 20,
30, 40 µl) were added to the oGH -15 standard dilutions.
The interference of the added amounts of plasma with
the calibration graph was observed. Because of this, all
standard dilutions were subsequently prepared in plasma,
which contained unmeasurable amounts of endogenous
oGH (≤ 0.38 ± 0.02 ng ml-1). The samples and standards
were standardised to a volume of 40 µl per well to
guarantee sufficient assay sensitivity (Figure 2). Using
standards prepared in plasma, the recovery rates of
various concentrations of pit. oGH-15 (3.13, 6.25,
12.50 ng ml-1) added to unknown samples were
determined and acceptable results were obtained (Table
1).
At a volume of 40 µl of standards per well the
detection limit of the assay (optical density values
significantly different from those at 100 % B / B0) was
found to be 0.38 ± 0.02 ng per ml of pit. oGH-15 (Mean
± S.D., n = 19, R.S.D. = 5.34) and 50 % relative binding
(B / B0) occurred at 3.80 ± 0.18 ng ml-1 pit. oGH-15
(Mean ± S.D., n=19, R.S.D. = 4.36).
Intra- and Inter-assay Variation
Intra- and inter-assay variation was determined using
plasma samples with various pit-oGH concentrations
(Mean ± S.D.) of 3.39 ± 0.12 (n=11) and 13.45 ± 0.42
(n=10) of pit. oGH, resulting in R.S.D.s of 10.44 and
9.84 %. The interassay variation was 10.26 and 5.03
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Figure 1.

Influence of incubation period and temperature on oGH binding.
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Table 1.

Recoveries of pituitary-derived GH added to different
plasma samples at various concentrations.

Plasma oGH
ng/ml

Added Pit oGH-15
ng/ml

Recovery
%

Variation
%

0.91
0.91
0.91

3.13
6.25
12.50

96.78
92.18
100.03

5.81
7.97
9.84

using plasma samples with concentrations of 6.81 ± 0.11
(n=20) and 12.48 ± 0.11 (n=20) ng ml-1 of pit. oGH,
respectively.
Cross-reactivity with other hormones
NIDDK-oGH-2 rabbit antiserum, which has the same
affinity as NIDDK oGH-1-4, was obtained from the
National Hormones and Pituitary Program (NIDKK,
Baltimore, Maryland, USA). This antiserum undergoes no
cross reactions with other hormones (oFSH, oLH, oTSH
and oPRL).
Clinical Validation
Plasma samples were collected every 15 min. from
the bleeding vena jugularis of a Merino lamb and an
Akkaraman ram lamb by a permanent catheter, and the
oGH levels of the samples were analysed as described in
materials and methods. Both animals were injected with
8 µl kg-1 Human Growth Hormone Releasing Factor
(hGRF 1-29, Saxon Biochemicals, Hanover, Germany) and
then the samples were collected to observe the responses.
The Akkaraman sheep’s response to stimulation was
smaller and slower than that in the Merino sheep (Figure
3). The Akkaraman lamb exhibited a GH response 20 min
after stimulation while the Merino lamb responded only
10 min after stimulation and this implied that the
Akkaraman has a slow and weak response to GH
stimulation.
Discussion
There has been no information published concerning
plasma oGH level analysis using EIA methods. The
method developed in this study is the first EIA method to
analyse sheep plasma oGH levels. To date, sheep plasma
GH levels have been analysed using RIA methods. EIA
analyses have been preferred to RIA, because EIA requires
less expensive equipment, does not create hazards for the
environment or human health and has long-life tracers.
Recently, EIA methods have become popular in hormonal
detection and EIA methods have been developed for
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bovine LH, porcine GH (pGH), progesterone, and
ostradiol 17β (9-11). It has been reported that EIA
methods are optimised by coating the plate wells with
secondary antibody using goat or sheep anti rabbit IgG
(12). The amount of required hormone specific antibody
for EIA has been found to be 10 times less than for RIA
and 1000 times less than for sandwich ELISA (12).
In this study, 1:500,000 optimum dilutions were used
for double side titration analyses after coating the plate
wells with secondary antibody. This dilution was much
lower than that used by Pell and Asthon (13), 1: 500
dilutions for oGH analyses with RIA. This shows that the
same amount of antiserum can be used for more EIA
analyses.
The incubation period of oGH assays for RIA is 3 to 5
days (2,14) while the incubation period for EIA is 48 h (2
days). This indicates that EIA analysis methods are faster
than RIA.
The required quantity of the plasma samples (40 µl)
in EIA does not affect the sensitivity of the analyses
(Figure 2). It has been reported that 0.5 ng ml–1 is the
minimal amount of RIA detection (14,15). In this study,
it has been shown that the GH detection level of EIA
sensitivity is not less than that of RIA methods. The
minimum detection limit for the EIA method was found
to be 0.38 ± 0.02 ng ml–1 and the relative binding value
was 3.8 ± 0.18 ng ml–1.
Interassay and intraassay variation tests have been
developed for different animal species in order to assess
the repeatability of GH – RIA methods (15-18). The
difference between intraassay variations have been
reported as 5% to 13% and interassay variations as 11%
to 20% (15,16,18). In this project, intraassay variations
were found to be 10.44% and 9.84%, using two
different plasma samples containing different levels of GH
(3.39 ± 0.12 and 13.45 ± 0.42 ng ml–1). The difference
between interassay variations were 10.26 % and 5.03%
in two different plasma samples (6.18 ± 0.11 and 12.48
± 0.11). These findings are in agreement with RIA
variations.
The reliability of the developed EIA was checked using
a recovery test. 3.13, 6.25 and 12.50 ng ml–1 of oGH
were added to samples and recorvery rates of 97.6 %,
92.18 % and 100.03 % respectively were obtained. The
variations were found to be 5.8 %, 7.97 % and 9.84 %
respectively for the recovery tests (Table 1).
The utility of the developed EIA was checked using an
Akkaraman lamb and a Merino lamb by injecting
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Figure 2.

Influence of volume of standard on oGH binding.

intravenously 8 µg kg–1 body weight hGRF 1-29 after
determining the basal level of oGH. It was found that EIA
can detect the response of GRF stimulations at basal
levels (Figure 3). This study shows that EIA is a reliable
and sensitive detection method for plasma oGH level.
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